Granite Point Capital Management, L.P. 9 Meters Biopharma, Inc. Transaction History

Granite Point Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Nov 06, 2020	SELL	$0.48 - $0.84 $521,772 - $913,101	-1,087,026 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$0.43 - $0.74 $467,421 - $804,399	1,087,026 New	1,087,026 $623,000

73.4K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.